The stock price of Alzamend Neuro Inc (NASDAQ: ALZN) has dropped by -20.02 compared to previous close of 0.70. Despite this, the company has seen a fall of -20.83% in its stock price over the last five trading days. InvestorPlace reported 2023-05-24 that Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech stocks that have 10X potential, or better.
Is It Worth Investing in Alzamend Neuro Inc (NASDAQ: ALZN) Right Now?
Additionally, the 36-month beta value for ALZN is 0.14. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALZN is 4.83M and currently, short sellers hold a 0.30% ratio of that float. The average trading volume of ALZN on May 08, 2024 was 57.05K shares.
ALZN’s Market Performance
The stock of Alzamend Neuro Inc (ALZN) has seen a -20.83% decrease in the past week, with a -36.03% drop in the past month, and a -36.82% fall in the past quarter. The volatility ratio for the week is 17.31%, and the volatility levels for the past 30 days are at 9.86% for ALZN. The simple moving average for the past 20 days is -24.81% for ALZN’s stock, with a -73.73% simple moving average for the past 200 days.
Analysts’ Opinion of ALZN
Many brokerage firms have already submitted their reports for ALZN stocks, with Ascendiant Capital Markets repeating the rating for ALZN by listing it as a “Buy.” The predicted price for ALZN in the upcoming period, according to Ascendiant Capital Markets is $8 based on the research report published on October 01, 2021 of the previous year 2021.
ALZN Trading at -37.24% from the 50-Day Moving Average
After a stumble in the market that brought ALZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.27% of loss for the given period.
Volatility was left at 9.86%, however, over the last 30 days, the volatility rate increased by 17.31%, as shares sank -38.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.84% lower at present.
During the last 5 trading sessions, ALZN fell by -20.83%, which changed the moving average for the period of 200-days by -92.21% in comparison to the 20-day moving average, which settled at $0.7311. In addition, Alzamend Neuro Inc saw -36.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALZN starting from AULT MILTON C III, who purchase 1,000 shares at the price of $0.69 back on Apr 19 ’24. After this action, AULT MILTON C III now owns 771,699 shares of Alzamend Neuro Inc, valued at $688 using the latest closing price.
AULT MILTON C III, the Director of Alzamend Neuro Inc, purchase 334 shares at $0.91 during a trade that took place back on Apr 01 ’24, which means that AULT MILTON C III is holding 770,699 shares at $304 based on the most recent closing price.
Stock Fundamentals for ALZN
The total capital return value is set at 4.17. Equity return is now at value -1489.09, with -265.15 for asset returns.
Based on Alzamend Neuro Inc (ALZN), the company’s capital structure generated -0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -19.0. The debt to equity ratio resting at -0.11. The interest coverage ratio of the stock is -1353.94.
Currently, EBITDA for the company is -14.85 million with net debt to EBITDA at -0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.16.
Conclusion
In conclusion, Alzamend Neuro Inc (ALZN) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
